Edited by:
Cristophe Nicot, PhD, Kansas University Medical Center, USA
Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.'
This Collection welcomes submission of Reviews and Correspondence Articles only.
Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.'
This Collection aims to showcase cutting-edge research in identification, validation, and clinical application of biomarkers that hold promise for accurate cancer diagnosis, prognosis, and prediction of drug resistance. We welcome Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. Please note that this Collection will not accept any study based on TCGA analyses without independent cohort validation.
Each Correspondence should start with “To the Editor”, include a maximum of 2 tables or figures, a maximum of 15 references and up to 1500 words in text. It should also have two subsections to better delineate the content, Abstract and Results/Discussion.
This Collection welcomes submission of Correspondence Articles only.
Image credit: © [M] freshidea / stock.adobe.com
Triple-negative breast cancer (TNBC) stands as the breast cancer subtype with the highest recurrence and mortality rates, with the lungs being the common site of metastasis. The pulmonary microenvironment play...
The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis t...
The identification of novel therapeutic strategies to overcome resistance to the MEK inhibitor trametinib in mutant KRAS lung adenocarcinoma (LUAD) is a challenge. This study analyzes the effects of trametinib on...
For decades, great strides have been made in the field of immunometabolism. A plethora of evidence ranging from basic mechanisms to clinical transformation has gradually embarked on immunometabolism to the cen...
Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges...
Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, ...
the problem in early diagnosis of sporadic cancer is understanding the individual’s risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models bas...
Bladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances. While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both ope...
Heat shock proteins play crucial roles in various biochemical processes, encompassing protein folding and translocation. HSP90B1, a conserved member of the heat shock protein family, growing evidences have dem...
Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TNBC, thus ...
The tumor microenvironment (TME) is an intricate system comprised of tumor cells and the surrounding cellular and non-cellular components, exerting a pivotal influence on the initiation and progression of tumo...
Clear cell renal cell carcinoma (ccRCC), as the most common histological subtype of kidney cancer, has been reported to originate primarily from proximal tubule (PT) cells in the kidney. However, the current r...
This Collection welcomes submission of Correspondence Articles only.
Please read our submission guidelines before submitting your article. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance" from the dropdown menu.
Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.